Bio-View Ltd Net Assets

Latest as of June 2025: ILA19.93 Million ILA ≈ $53.43K USD

Bio-View Ltd net assets. Based on the latest financial reports, Bio-View Ltd (BIOV) has net assets worth ILA19.93 Million ILA (≈ $53.43K USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA28.19 Million ≈ $75.57K USD) and total liabilities (ILA8.26 Million ≈ $22.13K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore BIOV net assets growth trend to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric Value
Current Net Assets ILA19.93 Million
% of Total Assets 70.71%
Annual Growth Rate 19.69%
5-Year Change -8.47%
10-Year Change -0.18%
Growth Volatility 106.95

Net Assets of Bio-View Ltd (2009–2024)

Net assets of Bio-View Ltd from 2009 to 2024. This chart illustrates how Bio-View Ltd's net assets have evolved over time, based on quarterly financial data. See Bio-View Ltd net asset quality index to measure how much of total assets are equity-financed.

Annual Net Assets for Bio-View Ltd (2009–2024)

The table below shows the annual net assets of Bio-View Ltd from 2009 to 2024. For live market cap and overall valuation, see Bio-View Ltd market capitalisation.

Year Net Assets Change
2024-12-31 ILA22.95 Million
≈ $61.52K		 -15.96%
2023-12-31 ILA27.30 Million
≈ $73.20K		 -3.43%
2022-12-31 ILA28.28 Million
≈ $75.81K		 +4.11%
2021-12-31 ILA27.16 Million
≈ $72.82K		 +8.34%
2020-12-31 ILA25.07 Million
≈ $67.21K		 +0.48%
2019-12-31 ILA24.95 Million
≈ $66.89K		 +9.68%
2018-12-31 ILA22.75 Million
≈ $60.99K		 -3.01%
2017-12-31 ILA23.45 Million
≈ $62.88K		 -15.03%
2016-12-31 ILA27.61 Million
≈ $74.01K		 +20.08%
2015-12-31 ILA22.99 Million
≈ $61.63K		 +26.43%
2014-12-31 ILA18.18 Million
≈ $48.75K		 +16.19%
2013-12-31 ILA15.65 Million
≈ $41.95K		 -6.26%
2012-12-31 ILA16.69 Million
≈ $44.76K		 +9.84%
2011-12-31 ILA15.20 Million
≈ $40.75K		 +85.89%
2010-12-31 ILA8.18 Million
≈ $21.92K		 +428.17%
2009-12-31 ILA1.55 Million
≈ $4.15K		 --

Equity Component Analysis

This analysis shows how different components contribute to Bio-View Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 2695800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Bio-View Ltd Net Assets Breakdown (December 2024)

Bio-View Ltd net assets breakdown by equity component as of December 2024.

Component Amount Percentage
Other Components ILA49.90 Million 217.48%
Total Equity ILA22.95 Million 100.00%

Bio-View Ltd Competitors by Market Cap

The table below lists competitors of Bio-View Ltd ranked by their market capitalization.

Company Market Cap
Mostostal Warszawa S.A.
WAR:MSW
 $20.37 Million
Perpetuals.com Ltd
NASDAQ:PDC
 $20.37 Million
S&K Polytec Co. Ltd
KQ:091340
 $20.38 Million
Flexiroam Ltd
AU:FRX
 $20.39 Million
Diagnos Laboratorium Utama PT Tbk
JK:DGNS
 $20.36 Million
Mgenplus Co. Ltd.
KQ:032790
 $20.36 Million
Bankers Investment Trust
LSE:BNKR
 $20.36 Million
JPEL Private Equity Ltd
LSE:JPEL
 $20.35 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Bio-View Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 27,305,000 to 22,946,000, a change of -4,359,000 (-16.0%).
  • Net loss of 3,148,000 reduced equity.
  • Share repurchases of 1,400,000 reduced equity.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income ILA-3.15 Million -13.72%
Share Repurchases ILA1.40 Million -6.1%
Other Changes ILA189.00K +0.82%
Total Change ILA- -15.96%

Book Value vs Market Value Analysis

This analysis compares Bio-View Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 354.67x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 37.42x to 354.67x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-12-31 ILA1.68 ILA62.85 x
2018-12-31 ILA1.63 ILA62.85 x
2019-12-31 ILA1.75 ILA62.85 x
2020-12-31 ILA1.83 ILA62.85 x
2021-12-31 ILA1.98 ILA62.85 x
2022-12-31 ILA2.07 ILA62.85 x
2023-12-31 ILA0.20 ILA62.85 x
2024-12-31 ILA0.18 ILA62.85 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Bio-View Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -13.72%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -12.27%
  • • Asset Turnover: 0.76x
  • • Equity Multiplier: 1.47x
  • Recent ROE (-13.72%) is below the historical average (14.03%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2009 72.16% 4.96% 1.53x 9.48x ILA962.20K
2010 64.04% 20.68% 1.18x 2.62x ILA4.42 Million
2011 43.27% 25.13% 0.89x 1.94x ILA5.06 Million
2012 8.64% 5.54% 0.87x 1.79x ILA-227.40K
2013 -6.88% -4.67% 0.83x 1.78x ILA-2.64 Million
2014 11.59% 6.97% 0.97x 1.71x ILA289.80K
2015 17.69% 11.77% 1.03x 1.45x ILA1.77 Million
2016 16.07% 13.33% 0.86x 1.40x ILA1.68 Million
2017 -5.34% -4.51% 0.80x 1.48x ILA-3.60 Million
2018 -8.15% -7.33% 0.76x 1.47x ILA-4.13 Million
2019 10.12% 7.06% 0.97x 1.48x ILA30.00K
2020 3.53% 3.41% 0.77x 1.35x ILA-1.62 Million
2021 8.04% 7.16% 0.76x 1.47x ILA-532.00K
2022 2.08% 2.01% 0.70x 1.48x ILA-2.24 Million
2023 1.40% 1.10% 0.83x 1.54x ILA-2.35 Million
2024 -13.72% -12.27% 0.76x 1.47x ILA-5.44 Million

Industry Comparison

This section compares Bio-View Ltd's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $18,956,222
  • Average return on equity (ROE) among peers: -59.59%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Bio-View Ltd (BIOV) ILA19.93 Million 72.16% 0.41x $20.36 Million
Allmed Solutions Ltd (ALMD) $53.96 Million -20.74% 0.07x $7.88 Million
Erika Carmel Ltd (BCUR) $15.04 Million -62.98% 1.31x $4.69 Million
Brainsway Ltd (BWAY) $6.95 Million -93.20% 2.39x $394.54 Million
Erech Finance Cahalacha Ltd (EFNC) $28.37 Million -88.27% 1.44x $816.18K
Epitomee Medical Ltd (EPIT) $33.95 Million -15.68% 0.18x $28.14 Million
Erika Carmel-Tech Ltd (ERKA) $8.97 Million 138.94% 4.32x $4.46 Million
Human Xtensions Ltd (HUMX) $15.51 Million -184.33% 0.31x $2.12 Million
Pulsenmore Ltd (PULS) $3.75 Million -126.31% 0.60x $22.89 Million
Sofwave Medical Ltd (SOFW) $4.12 Million -83.72% 0.51x $357.45 Million

About Bio-View Ltd

TA:BIOV Israel Medical Devices
Market Cap
$21.82 Million
ILA8.14 Billion ILA
Market Cap Rank
#24902 Global
#358 in Israel
Share Price
ILA62.85
Change (1 day)
+4.75%
52-Week Range
ILA11.90 - ILA131.90
All Time High
ILA5076.00
Categories
Companies in Israel Medical Devices
About

Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company's products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatic… Read more